Relaxin signals through a RXFP1-pERK-nNOS-NO-cGMP-dependent pathway to up-regulate matrix metalloproteinases: The additional involvement of iNOS

PLoS ONE

Volumn 7, Issue 8, 2012, Pages

  Chow, Bryna Suet Man ^a   Chew, Elaine Guo Yan ^a,d   Zhao, Chongxin ^a   Bathgate, Ross A D ^a   Hewitson, Tim D ^a,b   Samuel, Chrishan S ^a,c  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b ROYAL MELBOURNE HOSPITAL   (Australia)

^c MONASH UNIVERSITY   (Australia)

^d GENOME INSTITUTE OF SINGAPORE   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; COLLAGENASE 3; CYCLIC GMP; GELATINASE A; GELATINASE B; GUANYLATE CYCLASE; HORMONE RECEPTOR; INDUCIBLE NITRIC OXIDE SYNTHASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; N(G) NITROARGININE METHYL ESTER; NEURONAL NITRIC OXIDE SYNTHASE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE INHIBITOR; RELAXIN; RELAXIN FAMILY PEPTIDE RECEPTOR 1; TRANSFORMING GROWTH FACTOR BETA1; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL CELL CULTURE; ANIMAL TISSUE; ARTICLE; CELL ISOLATION; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME REGULATION; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; KIDNEY PARENCHYMA; MALE; MYOFIBROBLAST; NONHUMAN; PROTEIN EXPRESSION; RAT; SIGNAL TRANSDUCTION; SKIN FIBROBLAST; UPREGULATION; WESTERN BLOTTING; ZYMOGRAPHY;

ANIMALS; CELL LINE; CELLS, CULTURED; CYCLIC GMP; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FIBROBLASTS; HUMANS; KIDNEY; MALE; MATRIX METALLOPROTEINASE 13; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MATRIX METALLOPROTEINASES; MICE; MICE, KNOCKOUT; NITRIC OXIDE; NITRIC OXIDE SYNTHASE TYPE I; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, G-PROTEIN-COUPLED; RECEPTORS, PEPTIDE; RELAXIN; SIGNAL TRANSDUCTION;

EID: 84865168929     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0042714     Document Type: Article

References (61)

1. Wynn TA, (2008) Cellular and molecular mechanisms of fibrosis. J Pathol 214: 199-210.
2. Franklin TJ, (1997) Therapeutic approaches to organ fibrosis. Int J Biochem Cell Biol 29: 79-89.
3. Becker GJ, Hewitson TD, (2000) The role of tubulointerstitial injury in chronic renal failure. Curr Opin Nephrol Hypertens 9: 133-138.
4. Powell DW, Mifflin RC, Valentich JD, Crowe SE, Saada JI, et al. (1999) Myofibroblasts. I. Paracrine cells important in health and disease. Am J Physiol 277: C1-C9.
5. Weber KT, (1989) Cardiac interstitium in health and disease: the fibrillar collagen network. J Am Coll Cardiol 13: 1637-1652.
6. Eddy AA, (2000) Molecular basis of renal fibrosis. Pediatr Nephrol 15: 290-301.
7. Li YY, McTiernan CF, Feldman AM, (2000) Interplay of matrix metalloproteinases, tissue inhibitors of metalloproteinases and their regulators in cardiac matrix remodeling. Cardiovasc Res 46: 214-224.
8. Sherwood OD, (2004) Relaxin's physiological roles and other diverse actions. Endocr Rev 25: 205-234.
9. Bathgate RAD, Hsueh AJ, Sherwood OD (2006) Physiology and Molecular Biology of the Relaxin Peptide Family. In: Neill JD, editor. Physiology of Reproduction, 3rd ed. San Diego: Elsevier. pp. 679-770.
10. Nistri S, Bigazzi M, Bani D, (2007) Relaxin as a cardiovascular hormone: physiology, pathophysiology and therapeutic promises. Cardiovasc Hematol Agents Med Chem 5: 101-108.
11. Samuel CS, Hewitson TD, Unemori EN, Tang ML, (2007) Drugs of the future: the hormone relaxin. Cell Mol Life Sci 64: 1539-1557.
12. Bennett RG, (2009) Relaxin and its role in the development and treatment of fibrosis. Transl Res 154: 1-6.
13. Du XJ, Bathgate RA, Samuel CS, Dart AM, Summers RJ, (2010) Cardiovascular effects of relaxin: from basic science to clinical therapy. Nat Rev Cardiol 7: 48-58.
14. Jeyabalan A, Shroff SG, Novak J, Conrad KP, (2007) The vascular actions of relaxin. Adv Exp Med Biol 612: 65-87.
15. Teichman SL, Unemori E, Dschietzig T, Conrad K, Voors AA, et al. (2009) Relaxin, a pleiotropic vasodilator for the treatment of heart failure. Heart Fail Rev 14: 321-329.
16. Unemori EN, Lewis M, Constant J, Arnold G, Grove BH, et al. (2000) Relaxin induces vascular endothelial growth factor expression and angiogenesis selectively at wound sites. Wound Repair Regen 8: 361-370.
17. Moore XL, Tan SL, Lo CY, Fang L, Su YD, et al. (2007) Relaxin antagonizes hypertrophy and apoptosis in neonatal rat cardiomyocytes. Endocrinology 148: 1582-1589.
18. Hewitson TD, Ho WY, Samuel CS, (2010) Antifibrotic properties of relaxin: in vivo mechanism of action in experimental renal tubulointerstitial fibrosis. Endocrinology 151: 4938-4948.
19. Samuel CS, Cendrawan S, Gao XM, Ming Z, Zhao C, et al. (2011) Relaxin remodels fibrotic healing following myocardial infarction. Lab Invest 91: 675-690.
20. Mookerjee I, Hewitson TD, Halls ML, Summers RJ, Mathai ML, et al. (2009) Relaxin inhibits renal myofibroblast differentiation via RXFP1, the nitric oxide pathway, and Smad2. FASEB J 23: 1219-1229.
21. Heeg MH, Koziolek MJ, Vasko R, Schaefer L, Sharma K, et al. (2005) The antifibrotic effects of relaxin in human renal fibroblasts are mediated in part by inhibition of the Smad2 pathway. Kidney Int 68: 96-109.
22. Hossain MA, Man BC, Zhao C, Qu X, Du XJ, et al. (2011) H3 relaxin demonstrates antifibrotic properties via the RXFP1 receptor. Biochemistry 50: 1368-1375.
23. Masterson R, Hewitson TD, Kelynack K, Martic M, Parry L, et al. (2004) Relaxin down-regulates renal fibroblast function and promotes matrix remodelling in vitro. Nephrol Dial Transplant 19: 544-552.
24. Samuel CS, Unemori EN, Mookerjee I, Bathgate RA, Layfield SL, et al. (2004) Relaxin modulates cardiac fibroblast proliferation, differentiation and collagen production and reverses cardiac fibrosis in vivo. Endocrinology 145: 4125-4133.
25. Unemori EN, Pickford LB, Salles AL, Piercy CE, Grove BH, et al. (1996) Relaxin induces an extracellular matrix-degrading phenotype in human lung fibroblasts in vitro and inhibits lung fibrosis in a murine model in vivo. J Clin Invest 98: 2739-2745.
26. Unemori EN, Amento EP, (1990) Relaxin modulates synthesis and secretion of procollagenase and collagen by human dermal fibroblasts. J Biol Chem 265: 10681-10685.
27. Bennett RG, Kharbanda KK, Tuma DJ, (2003) Inhibition of markers of hepatic stellate cell activation by the hormone relaxin. Biochem Pharmacol 66: 867-874.
28. Palejwala S, Stein DE, Weiss G, Monia BP, Tortoriello D, et al. (2001) Relaxin positively regulates matrix metalloproteinase expression in human lower uterine segment fibroblasts using a tyrosine kinase signaling pathway. Endocrinology 142: 3405-3413.
29. Naqvi T, Duong TT, Hashem G, Shiga M, Zhang Q, et al. (2005) Relaxin's induction of metalloproteinases is associated with the loss of collagen and glycosaminoglycans in synovial joint fibrocartilaginous explants. Arthritis Res Ther 7: R1-R11.
30. Lekgabe ED, Kiriazis H, Zhao C, Xu Q, Moore XL, et al. (2005) Relaxin reverses cardiac and renal fibrosis in spontaneously hypertensive rats. Hypertension 46: 412-418.
31. Hossain MA, Rosengren KJ, Samuel CS, Shabanpoor F, Chan LJ, et al. (2011) The minimal active structure of human relaxin-2. J Biol Chem 286: 37555-37565.
32. Hahn WC, Counter CM, Lundberg AS, Beijersbergen RL, Brooks MW, et al. (1999) Creation of human tumour cells with defined genetic elements. Nature 400: 464-468.
33. Diamond JR, Ricardo SD, Klahr S, (1998) Mechanisms of interstitial fibrosis in obstructive nephropathy. Semin Nephrol 18: 594-602.
34. Rodemann HP, Muller GA, (1990) Abnormal growth and clonal proliferation of fibroblasts derived from kidneys with interstitial fibrosis. Proc Soc Exp Biol Med 195: 57-63.
35. Zhang HY, Phan SH, (1999) Inhibition of myofibroblast apoptosis by transforming growth factor beta(1). Am J Respir Cell Mol Biol 21: 658-665.
36. Vodovotz Y, Bogdan C, Paik J, Xie QW, Nathan C, (1993) Mechanisms of suppression of macrophage nitric oxide release by transforming growth factor beta. J Exp Med 178: 605-613.
37. Junquero DC, Scott-Burden T, Schini VB, Vanhoutte PM, (1992) Inhibition of cytokine-induced nitric oxide production by transforming growth factor-beta 1 in human smooth muscle cells. J Physiol 454: 451-465.
38. Bathgate RAD, Lin F, Hanson NF, Otvos L Jr, Guidolin A, et al. (2006) Relaxin-3: Improved synthesis strategy and demonstration of its high affinity interaction with the relaxin receptor LGR7 both in vitro and in vivo. Biochemistry 45: 1043-1053.
39. Samuel CS, Hewitson TD, Zhang Y, Kelly DJ, (2008) Relaxin ameliorates fibrosis in experimental diabetic cardiomyopathy. Endocrinology 149: 3286-3293.
40. Samuel CS, Zhao C, Bathgate RA, Bond CP, Burton MD, et al. (2003) Relaxin deficiency in mice is associated with an age-related progression of pulmonary fibrosis. FASEB J 17: 121-123.
41. Woessner JF Jr, (1995) Quantification of matrix metalloproteinases in tissue samples. Methods Enzymol 248: 510-528.
42. Mu X, Urso ML, Murray K, Fu F, Li Y, (2010) Relaxin regulates MMP expression and promotes satellite cell mobilization during muscle healing in both young and aged mice. Am J Pathol 177: 2399-2410.
43. Royce SG, Miao YR, Lee M, Samuel CS, Tregear GW, et al. (2009) Relaxin reverses airway remodeling and airway dysfunction in allergic airways disease. Endocrinology 150: 2692-2699.
44. Woessner JF Jr, (1991) Matrix metalloproteinases and their inhibitors in connective tissue remodeling. FASEB J 5: 2145-2154.
45. Aimes RT, Quigley JP, (1995) Matrix metalloproteinase-2 is an interstitial collagenase. Inhibitor-free enzyme catalyzes the cleavage of collagen fibrils and soluble native type I collagen generating the specific 3/4- and 1/4-length fragments. J Biol Chem 270: 5872-5876.
46. Visse R, Nagase H, (2003) Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and biochemistry. Circ Res 92: 827-839.
47. Nagase H, Visse R, Murphy G, (2006) Structure and function of matrix metalloproteinases and TIMPs. Cardiovasc Res 69: 562-573.
48. Pini A, Shemesh R, Samuel CS, Bathgate RA, Zauberman A, et al. (2010) Prevention of bleomycin-induced pulmonary fibrosis by a novel antifibrotic peptide with relaxin-like activity. J Pharmacol Exp Ther 335: 589-599.
49. Huang X, Gai Y, Yang N, Lu B, Samuel CS, et al. (2011) Relaxin Regulates Myofibroblast Contractility and Protects against Lung Fibrosis. Am J Pathol 179: 2751-2765.
50. Masini E, Zagli G, Ndisang JF, Solazzo M, Mannaioni PF, et al. (2002) Protective effect of relaxin in cardiac anaphylaxis: involvement of the nitric oxide pathway. Br J Pharmacol 137: 337-344.
51. Bani D, Failli P, Bello MG, Thiemermann C, Bani Sacchi T, et al. (1998) Relaxin activates the L-arginine-nitric oxide pathway in vascular smooth muscle cells in culture. Hypertension 31: 1240-1247.
52. Persichini T, Cantoni O, Suzuki H, Colasanti M, (2006) Cross-talk between constitutive and inducible NO synthase: an update. Antioxid Redox Signal 8: 949-954.
53. McGuane JT, Debrah JE, Sautina L, Jarajapu YP, Novak J, et al. (2011) Relaxin induces rapid dilation of rodent small renal and human subcutaneous arteries via PI3 kinase and nitric oxide. Endocrinology 152: 2786-2796.
54. Moncada S, Palmer RM, Higgs EA, (1991) Nitrix oxide: physiology, pathophysiology, and pharmacology. Pharmacol rev 43: 109-142.
55. Baccari MC, Calamai F, Chiappini L, Vannucchi MG, Bani D, (2005) Relaxin restores altered ileal spontaneous contractions in dystrophic (mdx) mice. Ann N Y Acad Sci 1041: 308-310.
56. Ferreira VM, Gomes TS, Reis LA, Ferreira AT, Razvickas CV, et al. (2009) Receptor-induced dilatation in the systemic and intrarenal adaptation to pregnancy in rats. PLoS One 4: e4845.
57. Miyazaki D, Nakamura A, Fukushima K, Yoshida K, Takeda S, et al. (2011) Matrix metalloproteinase-2 ablation in dystrophin-deficient mdx muscles reduces angiogenesis resulting in impaired growth of regenerated muscle fibers. Hum Mol Genet 20: 1787-1799.
58. Conrad KP, (2011) Maternal vasodilation in pregnancy: the emerging role of relaxin. Am J Physiol Regul Integr Comp Physiol 301: R267-R275.
59. Franchi A, Santucci M, Masini E, Sardi I, Paglierani M, et al. (2002) Expression of matrix metalloproteinase 1, matrix metalloproteinase 2, and matrix metalloproteinase 9 in carcinoma of the head and neck. Cancer 95: 1902-1910.
60. Filippin LI, Cuevas MJ, Lima E, Marroni NP, Gonzalez-Gallego J, et al. (2011) Nitric oxide regulates the repair of injured skeletal muscle. Nitric Oxide 24: 43-49.
61. Kang EH, Lee YJ, Kim TK, Chang CB, Chung JH, et al. (2010) Adiponectin is a potential catabolic mediator in osteoarthritis cartilage. Arthritis Res Ther 12: R231.